Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01126268
Other study ID # HSC-MS-09-0650
Secondary ID
Status Completed
Phase Phase 4
First received April 19, 2010
Last updated January 20, 2016
Start date April 2010
Est. completion date November 2012

Study information

Verified date January 2016
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections including secondarily infected eczema presumed to be caused by methicillin resistant Staph aureus. Male and female patients ages 9 months to 98 years will be recruited from a university based dermatology clinic. Upon enrollment, wound cultures will be collected, and then subjects will apply topical retapamulin twice daily for five days. The primary endpoint will be resolution of methicillin-resistant Staphylococcus aureus (MRSA) infection based on clinical presentation and physical exam, as well as bacteriological efficacy based on culture results. It is anticipated that approximately 75 patients will be enrolled, with expectation that approximately 50 of these patients will have MRSA infections.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date November 2012
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 9 Months to 98 Years
Eligibility Inclusion Criteria:

- Male or female patients from 9 months of age up to 98 years of age.

- Clinical diagnosis of impetigo, folliculitis, or minor soft tissue infection including secondarily infected eczema presumed to be caused by Staphylococcus aureus.

- The patient, and if applicable the parent or guardian, is able to give informed consent

- Females of child bearing potential have a negative urine pregnancy test.

- Patient, and if applicable parent or guardian, are willing to and capable of complying with the study protocol.

Exclusion Criteria:

- Subject who has used a topical antibacterial medication to the area being treated within the last 48 hours.

- Subject who has been enrolled in a clinical trial within the last 30 days.

- Subject with signs of systemic infection (such as fever), or with evidence of abscess or cellulitis at the site to be treated.

- Subject has a bacterial skin infection which would not be appropriately treated by a topical antibiotic in the opinion of the investigator

- Subjects who have taken oral antibiotics within the last 7 days.

- Subjects with known sensitivity to the study medication.

- The subject is pregnant or breastfeeding

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Retapamulin (Altabax)
Retapamulin ointment, applied topically twice daily for five days

Locations

Country Name City State
United States Houston Medical Center Building Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston GlaxoSmithKline

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bohaty BR, Choi S, Cai C, Hebert AA. Clinical and bacteriological efficacy of twice daily topical retapamulin ointment 1% in the management of impetigo and other uncomplicated superficial skin infections. International Journal of Women's Dermatology 1: 13

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Whose Wound Cultures Were Positive for MRSA and Who Were Determined to be a Clinical Success at the Follow-up Visit Clinical success is defined as no further signs or symptoms of infection present, including erythema, purulence, crusting, edema, warmth and pain. 6 to 8 days after treatment No
Secondary Clinical Response at Follow up as Assessed by a Rating Scale Clinical response was based on clinical evaluation by the investigator at the follow-up visit using a predefined scale with the following categories: (1) clinical success, (2) clinical improvement, (3) no change, (4) clinical failure, and (5) unable to determine. Patients who were designated as clinical success as defined in number 1 above were considered a true "clinical success" while all others were considered a "clinical failure." Patients were classified with an outcome of "unable to determine" if they missed their follow-up visit or refused clinical examination. 6 to 8 days after treatment No
Secondary Microbiologic Response at Follow up as Assessed by a Rating Scale Microbiological response was determined by the investigator at the follow-up visit using the following microbiological outcomes: (1) microbological eradication, (2) presumed microbiological eradication, (3) presumed microbiological improvement, (4) microbiological persistence, (5) presumed microbiological persistence, (6) unable to determine, (7) new pathogen, and (8) colonization. Patients who were designated microbiological eradication, presumed microbiological eradication, presumed microbiological improvement, or colonization as defined in numbers 1, 2, 3, and 8 above were considered a "microbiological success" while all others were considered "microbiological failure." 6 to 8 days after treatment No
Secondary Number of Participants Who Were a Therapeutic Success Therapeutic response was determined from the clinical response and the microbiological response. Patients who qualified as both a "clinical success" and a "microbiological success" were deemed a "therapeutic success," and all others were deemed "therapeutic failures." 6 to 8 days after treatment No
Secondary Erythema (Sign and Symptom of Infection) at Baseline Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. baseline No
Secondary Erythema (Sign and Symptom of Infection) at Follow up Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. 6 to 8 days after treatment No
Secondary Purulence (Sign and Symptom of Infection) at Baseline Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. baseline No
Secondary Purulence (Sign and Symptom of Infection) at Follow up Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. 6 to 8 days after treatment No
Secondary Crusting (Sign and Symptom of Infection) at Baseline Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. baseline No
Secondary Crusting (Sign and Symptom of Infection) at Follow up Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. 6 to 8 days after treatment No
Secondary Tissue Edema (Sign and Symptom of Infection) at Baseline Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. baseline No
Secondary Tissue Edema (Sign and Symptom of Infection) at Follow up Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. 6 to 8 days after treatment No
Secondary Tissue Warmth (Sign and Symptom of Infection) at Baseline Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. baseline No
Secondary Tissue Warmth (Sign and Symptom of Infection) at Follow up Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. 6 to 8 days after treatment No
Secondary Pain (Sign and Symptom of Infection) at Baseline Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. baseline No
Secondary Pain (Sign and Symptom of Infection) at Follow up Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. 6 to 8 days after treatment No
Secondary Wound Size at Baseline Wound size area was determined by measuring the greatest length of the wound in two perpendicular dimensions with a standard metric ruler. The two measurements were multiplied together to provide an estimate of the overall wound size. Surrounding erythema was not included in the measurement. baseline No
Secondary Wound Size at Follow up Wound size area was determined by measuring the greatest length of the wound in two perpendicular dimensions with a standard metric ruler. The two measurements were multiplied together to provide an estimate of the overall wound size. Surrounding erythema was not included in the measurement. 6 to 8 days after treatment No
Secondary Number of Participants Reporting Any Adverse Event (AE) AEs included burning at application site, upper respiratory infection, furuncle, cough, and a rash at a site other than the application site. See the Adverse Events section for more detailed information. baseline to 6 to 8 days after treatment Yes
See also
  Status Clinical Trial Phase
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT01153828 - EU PV for Retapamulin-Prescribing N/A
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Terminated NCT00986856 - Fucidin® Cream in the Treatment of Impetigo Phase 4
Completed NCT01397461 - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Phase 3
Recruiting NCT02090764 - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Phase 3
Completed NCT02775617 - Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Phase 4
Not yet recruiting NCT01611909 - Citriodiol® and Impetigo Phase 2/Phase 3
Completed NCT03177993 - Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji N/A
Completed NCT03429595 - Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo Phase 2
Completed NCT04287777 - Safety and Efficacy of Mupirocin Gel in Children With Impetigo Phase 3
Completed NCT00626795 - Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) Phase 2
Completed NCT00758862 - The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo Phase 2
Recruiting NCT01943136 - The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial Phase 1
Completed NCT01670032 - Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo Phase 2/Phase 3
Completed NCT01171326 - Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients Phase 2
Completed NCT01367314 - Safety and Efficacy of Topical NVC-422 Gel in Impetigo Phase 2
Completed NCT00852540 - Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA Phase 3
Completed NCT00133848 - Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment Phase 3